Fresenius SE & Co KGaA (FRE) Given a €83.00 Price Target at Sanford C. Bernstein

Fresenius SE & Co KGaA (FRA:FRE) has been given a €83.00 ($96.51) price target by Sanford C. Bernstein in a research note issued to investors on Monday. The firm currently has a “buy” rating on the stock. Sanford C. Bernstein’s target price suggests a potential upside of 20.46% from the stock’s previous close.

A number of other analysts also recently weighed in on FRE. Berenberg Bank set a €81.85 ($95.17) target price on shares of Fresenius SE & Co KGaA and gave the company a “buy” rating in a research report on Monday, June 11th. Goldman Sachs Group set a €72.00 ($83.72) target price on shares of Fresenius SE & Co KGaA and gave the company a “neutral” rating in a research report on Tuesday, June 12th. Barclays set a €78.50 ($91.28) target price on shares of Fresenius SE & Co KGaA and gave the company a “buy” rating in a research report on Tuesday, June 12th. Kepler Capital Markets set a €82.00 ($95.35) target price on shares of Fresenius SE & Co KGaA and gave the company a “buy” rating in a research report on Tuesday, June 12th. Finally, Deutsche Bank set a €84.00 ($97.67) target price on shares of Fresenius SE & Co KGaA and gave the company a “buy” rating in a research report on Tuesday, June 19th. One research analyst has rated the stock with a sell rating, five have given a hold rating and fifteen have issued a buy rating to the stock. Fresenius SE & Co KGaA presently has an average rating of “Buy” and a consensus target price of €77.79 ($90.46).

FRA:FRE opened at €68.90 ($80.12) on Monday. Fresenius SE & Co KGaA has a fifty-two week low of €60.16 ($69.95) and a fifty-two week high of €80.00 ($93.02).

About Fresenius SE & Co KGaA

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Featured Article: How to Use the New Google Finance Tool

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply